Radiopharmaceuticals - Naval Medical Center Portsmouth

The Defense Health Agency (DHA) is seeking a Firm Fixed Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to supply radiopharmaceuticals for the Naval Medical Center Portsmouth (NMCP) Radiology Department. The solicitation (HT940625R0004) requires a contractor to provide various nuclear medicine products including Technetium-99m, Iodine-123, Iodine-131, Fluorine-18 FDG, Copper-64, and Gallium-68 compounds. Key contract requirements include maintaining a 95% on-time delivery rate, routine deliveries by 7:00 AM on the day of use, and emergency deliveries within 2 hours of ordering. Proposals must include technical capabilities, past performance from three radiopharmaceutical contracts within the last 3 years, and small business participation documentation. The evaluation will be conducted on a best value basis, with past performance weighted more heavily than price, and questions from potential offerors were due by February 17, 2025, with proposals due by March 11, 2025 at 5:00 PM EST.

The solicitation is unrestricted, with no specific set-aside designations, and covers a five-year performance period from April 1, 2025 through March 31, 2030. The contract has a maximum order limitation of $4,000,000 and a guaranteed minimum of $100,000. The place of performance is Portsmouth, VA 23708, with detailed pricing exhibits specifying maximum annual quantities for various radiopharmaceuticals. Key volume requirements include 450 doses of F-18 FDG for PET imaging, 400 doses of Tc-99m Tetrofosmin for cardiac imaging, and 60 doses of Ga-68 Gozetotide. Additional services include weekday deliveries (first 3 free), after-hours delivery charges, and an annual software license support fee. The contractor must comply with all Nuclear Regulatory Commission (NRC) and Department of Transportation (DOT) regulations for radioactive materials handling, with a small business participation goal of 5%.